The first step to integrating the child's voice in adverse event reporting in oncology trials: A content validation study among pediatric oncology clinicians

被引:37
|
作者
Reeve, Bryce B. [1 ]
Withycombe, Janice S. [2 ]
Baker, Justin N. [3 ]
Hooke, Mary C. [4 ]
Lyons, Jessica C. [1 ]
Mowbray, Catriona [5 ]
Wang, Jichuan [5 ,6 ]
Freyer, David R. [7 ,8 ]
Joffe, Steven [9 ,10 ]
Sung, Lillian [11 ]
Tomlinson, Deborah [11 ]
Gold, Stuart H. [1 ]
Hinds, Pamela S. [5 ,6 ]
机构
[1] Univ N Carolina, Chapel Hill, NC 27599 USA
[2] Palmetto Hlth Childrens Hosp, Columbia, SC USA
[3] St Jude Childrens Res Hosp, Memphis, NC USA
[4] Univ Minnesota, Sch Nursing, Minneapolis, MN 55455 USA
[5] Childrens Natl Med Ctr, Washington, DC 20010 USA
[6] George Washington Univ, Sch Med, Washington, DC USA
[7] Childrens Hosp Los Angeles, Los Angeles, CA 90027 USA
[8] Univ So Calif, Los Angeles, CA USA
[9] Dana Farber Canc Inst, Boston, MA 02115 USA
[10] Boston Childrens Hosp, Boston, MA USA
[11] Hosp Sick Children, Toronto, ON M5G 1X8, Canada
关键词
adverse events; cancer; clinical trials; patient-reported outcomes; pediatric; validity; QUALITY-OF-LIFE; CANCER; ADOLESCENTS; CHEMOTHERAPY; SYMPTOMS; HEALTH; QUESTIONNAIRE; FATIGUE; PATIENT; VALIDITY;
D O I
10.1002/pbc.24463
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose Children with cancer experience significant toxicities while undergoing treatment. Documentation of adverse events (AEs) in clinical trials is mandated by federal agencies. Although many AEs are subjective, the current standard is clinician reporting. Our long-term goal is to create and validate a self-report measure of subjective AEs for children aged 7 years and older that will inform AE reporting for the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE). This content validation study aimed to identify which of the AEs in the current CTCAE should be included in a pediatric self-report measure. Methods We sought expert panel review and consensus among 187 pediatric clinicians from seven Children's Oncology Group institutions to determine which of the 790 AEs are amenable to child self-report. Two survey iterations were used to identify suitable AEs, and clinician agreement estimated by the content-validity ratio (CVR) was assessed. Results Response rates for surveys 1 and 2 were 72% and 67%, respectively. After the surveys, 64 CTCAE terms met the criteria of being subjective, relevant for use in pediatric cancer trials, and amenable to self-report by a child. The most frequent reasons for removal of CTCAE terms were that they relied on laboratory or clinical measures or were not applicable to children. Conclusion The 64 CTCAE terms will be translated into child-friendly terms as the basis of the child-report toxicity measure. Ultimately, systematic collection of these data will improve care by enhancing the accuracy and completeness of treatment toxicity reports for childhood cancer. Pediatr Blood Cancer 2013; 60: 12311236. (c) 2013 Wiley Periodicals, Inc.
引用
收藏
页码:1231 / 1236
页数:6
相关论文
共 10 条
  • [1] ELICITING THE CHILD'S VOICE IN ADVERSE EVENT REPORTING IN ONCOLOGY CLINICAL TRIALS.
    Hinds, Pamela
    Reeve, Bryce
    Jaobs, Shana
    Baker, Justin
    Mack, Jenny
    Withycom, Janice
    [J]. ONCOLOGY NURSING FORUM, 2017, 44 (02)
  • [2] Integrating the child's voice in adverse event reporting in oncology trials: cognitive interview findings from the multisite pediatric PRO-CTCAE initiative
    Reeve, Bryce B.
    McFatrich, Molly
    Baker, Justin N.
    Freyer, David R.
    Gagne, Joshua
    Gattuso, Jami S.
    Gibson, Deborah
    Kohler, Racquel E.
    Levine, Alyssa
    Lollar, Selena
    Lukshis, Jane
    Mack, Jennifer W.
    Martens, Christa
    Mowbray, Catriona
    Palma, Diana
    Pinheiro, Laura C.
    Sung, Lillian
    Taddei, Sarah C.
    Tomlinson, Deborah
    Waldron, Mia
    Weaver, Meaghann
    Wind, Jennifer
    Withycombe, Janice
    Hinds, Pamela S.
    [J]. QUALITY OF LIFE RESEARCH, 2015, 24 : 161 - 162
  • [3] Eliciting the child's voice in adverse event reporting in oncology trials: Cognitive interview findings from the Pediatric Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events initiative
    Reeve, Bryce B.
    McFatrich, Molly
    Pinheiro, Laura C.
    Weaver, Meaghann S.
    Sung, Lillian
    Withycombe, Janice S.
    Baker, Justin N.
    Mack, JenniferW.
    Waldron, Mia K.
    Gibson, Deborah
    Tomlinson, Deborah
    Freyer, David R.
    Mowbray, Catriona
    Jacobs, Shana
    Palma, Diana
    Martens, Christa E.
    Gold, Stuart H.
    Jackson, Kathryn D.
    Hinds, Pamela S.
    [J]. PEDIATRIC BLOOD & CANCER, 2017, 64 (03)
  • [4] Challenges and Barriers to Adverse Event Reporting in Clinical Trials: A Children's Oncology Group Report
    Miller, Tamara P.
    Marx, Melissa Z.
    Henchen, Christopher
    DeGroote, Nicholas P.
    Jones, Sally
    Weiland, Jenny
    Fisher, Beth
    Esbenshade, Adam J.
    Aplenc, Richard
    Dvorak, Christopher C.
    Fisher, Brian T.
    [J]. JOURNAL OF PATIENT SAFETY, 2022, 18 (03) : E672 - E679
  • [5] Improving infectious adverse event reporting for children and adolescents enrolled in clinical trials for acute lymphoblastic leukemia: A report from the Children's Oncology Group
    Elgarten, Caitlin W.
    Thompson, Joel C.
    Angiolillo, Anne
    Chen, Zhiguo
    Conway, Susan
    Devidas, Meenakshi
    Gupta, Sumit
    Kairalla, John A.
    McNeer, Jennifer L.
    O'Brien, Maureen M.
    Rabin, Karen R.
    Rau, Rachel E.
    Rheingold, Susan R.
    Wang, Cindy
    Wood, Charlotte
    Raetz, Elizabeth A.
    Loh, Mignon L.
    Alexander, Sarah
    Miller, Tamara P.
    [J]. PEDIATRIC BLOOD & CANCER, 2022, 69 (11)
  • [6] Accuracy of adverse event reporting on a phase III clinical trial for pediatric acute myeloid leukemia: A report from the Children's Oncology Group.
    Miller, Tamara P.
    Li, Yimei
    Kavcic, Marko
    Alonzo, Todd Allen
    Hall, Matt
    Huang, Yuan-Shung
    Gerbing, Robert B.
    Fisher, Brian
    Luger, Selina M.
    Rubin, David
    Troxel, Andrea B.
    Sung, Lillian
    Gamis, Alan S.
    Aplenc, Richard
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [7] Center-level variation in accuracy of adverse event reporting in a clinical trial for pediatric acute myeloid leukemia: a report from the Children's Oncology Group
    Miller, Tamara P.
    Li, Yimei
    Kavcic, Marko
    Getz, Kelly D.
    Huang, Yuan-Shun V.
    Sung, Lillian
    Alonzo, Todd A.
    Gerbing, Robert
    Daves, Marla H.
    Horton, Terzah M.
    Pulsipher, Michael A.
    Pollard, Jessica
    Bagatell, Rochelle
    Seif, Alix E.
    Fisher, Brian T.
    Luger, Selina
    Gamis, Alan S.
    Adamson, Peter C.
    Aplenc, Richard
    [J]. HAEMATOLOGICA, 2017, 102 (09) : E340 - E343
  • [8] Novel Approaches for Dynamic Visualization of Adverse Event Data in Oncology Clinical Trials: A Case Study Using Immunotherapy Trial S1400-I (SWOG)
    Lee, Shing M.
    Fan, Weijia
    Wang, Aijin
    Vaidya, Riha
    Redman, Mary W.
    Gettinger, Scott N.
    Bazhenova, Lyudmila
    Herbst, Roy S.
    Hershman, Dawn L.
    Unger, Joseph M.
    [J]. JCO CLINICAL CANCER INFORMATICS, 2023, 7
  • [9] Novel Approaches for Dynamic Visualization of Adverse Event Data in Oncology Clinical Trials: A Case Study Using Immunotherapy Trial S1400-I (SWOG)
    Lee, Shing M.
    Fan, Weijia
    Wang, Aijin
    Vaidya, Riha
    Redman, Mary W.
    Gettinger, Scott N.
    Bazhenova, Lyudmila
    Herbst, Roy S.
    Hershman, Dawn L.
    Unger, Joseph M.
    [J]. JCO CLINICAL CANCER INFORMATICS, 2023, 7
  • [10] Accuracy Of Adverse Event Reporting Compared To Patient Chart Abstraction On a Phase III NCI-Funded Clinical Trial For Pediatric Acute Myeloid Leukemia: A Report From The Children's Oncology Group
    Miller, Tamara P.
    Kavcic, Marko
    Li, Yimei
    Alonzo, Todd A.
    Hall, Matt
    Huang, Yuan-Shung
    Gerbing, Robert B.
    Fisher, Brian T.
    Luger, Selina
    Rubin, David
    Troxel, Andrea
    Sung, Lillian
    Gamis, Alan S.
    Aplenc, Richard
    [J]. BLOOD, 2013, 122 (21)